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Abstract
Background: Family physicians and other primary care practitioners are encouraged or expected to screen for an
expanding array of concerns and problems including intimate partner violence (IPV). While there is no debate
about the deleterious impact of violence and other adverse psychosocial exposures on health status, the key
question raised here is about the value of routine screening in primary care for such exposures.
Discussion: Several characteristics of IPV have led to consideration for routine IPV screening in primary care and
during other healthcare encounters (e.g., emergency room visits) including: its high prevalence, concern that it may
not be raised spontaneously if not prompted, and the burden of suffering associated with this exposure. Despite
these factors, there are now three randomized controlled trials showing that screening does not reduce IPV or
improve health outcomes. Yet, recommendations to routinely screen for IPV persist.
Similarly, adverse childhood experiences (ACEs) have several characteristics (e.g., high frequency, predictive power
of such experiences for subsequent health problems, and concerns that they might not be identified without
screening) suggesting they too should be considered for routine primary care screening. However, demonstration
of strong associations with health outcomes, and even causality, do not necessarily translate into the benefits of
routine screening for such experiences. To date, there have been no controlled trials examining the impact and
outcomes – either beneficial or harmful - of routine ACEs screening. Even so, there is an expansion of calls for
routine screening for ACEs.
Summary: While we must prioritize how best to support and intervene with patients who have experienced
IPV and other adverse psychosocial exposures, we should not be lulled into a false sense of security that our
routine use of “screeners” results in better health outcomes or less violence without evidence for such.
Decisions about implementation of routine screening for psychosocial concerns need similar rigorous debate
and scrutiny of empirical evidence as that recommended for proposed physical health screening (e.g., for
prostate and breast cancer).
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Background
Violence and other adverse psychosocial exposures are
increasingly understood as common and important influ-
ences on health status. One key consideration is how such
exposures can be easily identified within the context of
primary care settings. To address this challenge, various
screening tools have been developed and promoted for
use in primary care. An essential question, however, is
whether screening leads to actual health benefits.
There is no debate about the deleterious impact of
violence and other adverse psychosocial exposures on
health status, but the critical question remains: what is the
value of routine screening in primary care for such expo-
sures? The need to examine the evidence for this type of
screening is just as critical as the ongoing research about
the effectiveness of routine prostate specific antigen screen-
ing for prostate cancer or mammography screening for
breast cancer. All the basic principles of screening apply,
such as the accuracy of identification of a condition or
exposure, the acceptability of the test or screen, evidence of
health benefits for those screened positive, etc. [1].
Lessons could be learned from the careful considerations
of the evidence and resulting recommendations regarding
adult depression screening in primary care. Depression has
a number of characteristics that support its consideration
for primary care screening, including high prevalence,
availability of easy-to-use screening tools, and effective in-
terventions that could feasibly be delivered in primary care.
Despite this, positive health outcomes have not been con-
sistently demonstrated as a result of depression screening
in primary care, but potential risks have been flagged
(e.g., nocebo effects) [2]. These concerns contributed to
the Canadian Task Force on Preventive Health Care
(CTFPHC) recommending against routine depression
screening in primary care in their most recent state-
ment on screening for depression, a change from their
2005 recommendation [3].
The CTFPHC applied the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) ap-
proach in determining their recommendations [4]. In
contrast, the US Preventive Service Task Force (USPSTF)
uses a five level grading system with the top levels (A and
B indicating high certainty that the net benefit is substan-
tial or moderate, respectively) leading to USPSTF recom-
mending a given strategy, with a C level leading to a
selective or qualified recommendation [5]. The penulti-
mate American Academy of Family Physicians’ (AAFP)
recommendation for depression screening was informed
by a 2009 USPSTF report [6] and included contextual
considerations. More specifically, they issued a B grade
such that screening is recommended “when staff-assisted
depression care supports are in place,” but a Grade C, i.e.,
recommending against routine screening, when such sup-
ports are not in place [6]. In contrast, the 2016
recommendations from the USPSTF call for a more blanket
B grade (i.e., without the above caveat), although the ex-
panded text around this recommendation states that the
“Screening should be implemented with adequate systems
in place to ensure accurate diagnosis, effective treatment,
and appropriate follow-up (p. 380) [7]. The AAFP has now
adopted these new recommendations [8].
Discussion
The World Health Organization (WHO) defines IPV as
behaviour by a current or former intimate partner that
causes physical, sexual or psychological harm, including
acts of physical aggression, sexual coercion, psychological
abuse, and controlling behaviours [9]. Several characteris-
tics of IPV have led to consideration of routine IPV
screening in primary care and during other healthcare en-
counters (e.g., emergency room visits) including: high
prevalence, concern that issues may not be raised
spontaneously if not prompted, and the burden of suffer-
ing associated with this exposure. Despite these factors,
there are now three randomized controlled trials showing
that routine IPV screening does not reduce IPV or
improve health outcomes; one conducted in Canada with
patients recruited from 26 health care settings followed
for 18 months; a second carried out in a New Zealand
emergency department with a three-month follow-up and
the most recent, a US trial conducted in 10 primary health
care centers with a 1 year follow-up [10–12].
Despite these RCT findings, the USPSTF has given a
grade B rating and recommends that clinicians screen
women of childbearing age for IPV [13]. In addition,
promotion of this approach persists, including a mandate
for such screening within the US Affordable Care Act
[14]. It is not clear why the USPSTF does not appear to
have applied the same considerations with regard to
strength of evidence for IPV screening, as for other
exposures or conditions [15].
The extent to which countries outside the US are
engaged in, or promoting, routine IPV screening is not
known. However, related recommendations are being
made in at least some countries. For example, the UK
National Institute for Health and Care Excellence, within
an extensive list of recommendations on approaching
domestic violence and abuse, recommends that “…trained
staff in [a variety of healthcare areas] ask service users
whether they have experienced domestic violence and
abuse. This should be a routine part of good clinical
practice, even when there are no indicators of such
violence and abuse” (Recommendation 6) [16].
Other types of routine psychosocial risk factor screening
are also being promoted. For example, there have been
recent calls to screen for adverse childhood experiences
(ACEs) in adults. This in part stems from a cross-sectional
study of a US clinical sample demonstrating a graded
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association between increased number of ACEs and various
adult health problems [17]. Proponents of such screening
point to the high frequency of ACEs, the predictive power
of such experiences for subsequent health problems, and
concerns that they might not be identified without screen-
ing. However, demonstration of strong associations with
health outcomes, and even causality, does not necessarily
translate into benefits of routine screening for such factors
and identification of those at risk for adverse health
outcomes. To date there have been no controlled trials
examining the impact and outcomes – either beneficial or
harmful - of routine ACE screening.
The USPSTF has not provided a specific recommenda-
tion on ACE screening in primary care, however, in related
work (which was updated in 2013), they recommend, for
children who do not have signs or symptoms of maltreat-
ment, that “the current evidence is insufficient to assess the
balance of benefits and harms of primary care interventions
to prevent child maltreatment” [18]. Nevertheless, calls for
implementing ACE screening persist (e.g., a bill [H.299]
before the Vermont General Assembly proposing wide-
spread use of ACE screening in that state) [19]. Of note,
although the World Health Organization (WHO) is cur-
rently promoting the evaluation of an international ver-
sion of the ACE instrument, it does not recommend ACE
screening as a part of health services at this time [20].
Even in situations where the lack of evidence for
health benefits of screening for either IPV or child
maltreatment is acknowledged, a rationale for its use
may be framed as “it’s better than doing nothing”, “it
doesn’t hurt”, or “it’s important to increase awareness”.
Rationales such as these are problematic for several
reasons. There are finite resources to address the many
competing demands in primary care. Choosing to imple-
ment a given screening tool (and then dealing with the
response) entails “opportunity costs,” i.e., “by choosing
to use available resources in one way, we forgo other
opportunities to use these same resources” (p. 153) [21].
These activities may preclude addressing other health
issues or concerns raised by a patient. Additional costs,
beyond screening, may occur as a function of responses
to false positives. Unfortunately, there appears to be little
evaluation of trade-offs and considerations of relative
cost-benefits when it comes to these and other psycho-
social screening recommendations.
Beyond opportunity costs, risks for direct harm need to
be considered, including poor responses to true positives
and inappropriate responses to false positives. For example,
if screening correctly identifies IPV in a woman with
children and this leads to involvement of child protection
services with an investigation that results in the perpetrator
becoming aware of the process, this may place the woman
at greater risk of IPV exposure. In the case of a false
positive, a related harm could be a costly and stressful child
protection investigation where none was warranted. If such
risks are not addressed and there are no net benefits to the
screening, net harm is possible. As some screeners may
lead to over-identification [22], such concerns may be more
than theoretical.
Even among those correctly identified through screen-
ing, an important ethical issue is raised if such identifica-
tion is not “backed-up” with clear clinical pathways from
identification to effective interventions. In the American
Academy of Pediatrics’ call for an expanded role for
pediatricians in addressing ACEs, there is an acknow-
ledgement that there is “relatively limited availability of
evidence-based strategies …shown to reduce sources of
toxic stress in the lives of young children or mitigate
their adverse consequences” (p.e226) and that “routine
screening for increased vulnerability is useful only if
collaborative relationships exist with local services to
address the identified concerns…it is also essential that
those services demonstrate evidence of effectiveness”
(p.e227) [23]. They appropriately call for prioritizing
investment in evaluation of promising interventions
[23], hopefully as a pre-requisite to routine screening.
Summary
While we must prioritize how best to support and inter-
vene with patients who have experienced IPV and other
adverse psychosocial exposures, we should not be lulled
into a false sense of security that our routine use of
“screeners” results in better health outcomes or less
violence without evidence. Better mechanisms and
regulations are needed to ensure critical evaluations are
performed, and minimal standards are achieved, for
proposed screening before dissemination. In the case of
IPV, international guidelines from the WHO have now
moved beyond the concept of screening to instead focus
on safe, caring and effective case finding linked to
available services [24].
Conclusion
As is evident from the IPV literature, it has been
essential to examine the impact of screening, rather than
focusing only on how to screen, based on the erroneous
assumption that accurate screening will inevitably lead
to positive impacts. It is clear that decisions about any
and all health care screening, including within the
context of primary care, should be based on evidence.
The Choosing Wisely® initiative is one approach that
makes explicit recommendations on screening as well as
other medical procedures [25]. The AAFP is one of the
many partners in this initiative. Within their Choosing
Wisely recommendations, the AAFP provides an explicit
statement around prostate cancer screening, but there
are no directives around IPV or other adverse psycho-
social exposure screening. Hopefully such topics will be
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addressed as part of the Choosing Wisely recommenda-
tions in the near future. In the meantime, family physi-
cians and other primary care practitioners should be
alert to the clinical features associated with IPV; inquiry
about IPV exposure should occur in the context of case
finding and diagnostic assessment by clinicians compe-
tent to do so and able to respond appropriately through
referral and/or follow up. A similar approach is advo-
cated for other types of violence exposure such as child
maltreatment. It is essential that such inquiry take into
account issues of safety and avoidance of harm. Deci-
sions about implementation of approaches to identify
experiences of violence such as IPV, warrant the same
level of rigorous evaluation as other exposures and
health problems.
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